In obese patients bariatric surgery is increasing in popularity as a strategy to promote, and maintain, weight loss. In obese type 2 diabetes bypass, bariatric surgery improves glycaemic control — often to a greater extent than would be anticipated by weight loss alone. Surgical bypass procedures appear to initially offer a greater glucose-lowering effect than surgical restriction procedures. This review considers the rationale for bariatric surgery as a treatment for diabesity and the implications of the different procedures on the secretion and action of enteral hormones.
Scheen AJ, Lefèbvre PJManagement of the obese diabetic patient. Diabetes Reviews1999;7:77-93.
2.
Henry RR, Gumbiner B.Benefits and limitations of very-low calorie diet therapy in obese NIDDM. Diabetes Care1991;14:802-23.
3.
Wing RR, Koeske R., Epstein LH et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med1987;147:1749-53.
4.
Kelley DEEffects of weight loss on glucose homeostasis in NIDDM. Diabetes Reviews1995;3:366-77.
5.
Goldstein DJBeneficial health effects of modest weight loss . Int J Obes Relat Metab Disord1992;16:397-415.
6.
Pinkney J., Kerrigan D.When should bariatric surgery be used in the treatment of type 2 diabetes?Br J Diabetes Vasc Dis2004;4:232-7.
7.
Vetter ML, Cardillo S., Rickels MR, Iqbal N.Narrative review: effect of bariatric surgery on type 2 diabetes mellitus . Ann Intern Med2009;150:94-103.
8.
Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA2004;292:1724-37.
9.
Dixon JB, Pories WJ, O'Brien et al. Surgery as an effective early intervention for diabesity. Diabetes Care2005;28:472-4.
10.
Herbst CA, Hughes TA, Gwynne JT, Buckwalter KAGastric bariatric operation in insulin-treated adults. Surgery1984;95:209-14.
11.
Pories WJ, MacDonald KG, Flickinger EG et al. Is type II diabetes mellitus (NIDDM) a surgical disease?Ann Surg1992;215:633-43.
12.
Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg1995;222:339-50.
13.
MacDonald KG , Long SD, Swanson MS et al. The gastric bypass operation reduces the progression and mortality on non-insulin-dependent diabetes mellitus . J Gastrointest Surg1997;1:213-20.
14.
Schauer PR, Burguera B., Ikramuddin S. et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg2003;238:467-85.
15.
Sugerman HJ , Wolfe LG, Sica DA, Clore JNDiabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg2003;237:751-6.
16.
Scheen AJAggressive weight reduction treatment in the management of type 2 diabetes . Diabetes Metab1998;23:116-23.
17.
Pontiroli AE , Pizzocri P., Librenti MCLaparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab2002;87:3555-61.
18.
Sjostsrom L. , Lindroos AK, Peltonen M. et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med2004;351:2683-93.
19.
Ponce J., Haynes B., Paynter S. et al. Effect of Lap-Band-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg2004;14:1335-42.
20.
Dixon JB, O'Brien PEHealth outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care2002;25:358-63.
21.
Dixon JB, O'Brien PE, Playfair J. et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA2008;299:316-23.
22.
Flatt PR, Bailey CJ, Green BDRecent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab2009;10:125-37.
23.
Flatt PREffective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?Diabetes Vasc Dis Res2007;4:151-3.
Bailey CJ, Wilkes LC, Conlon JM et al. Effects of gastric inhibitory polypeptide, vasoactivie intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets. J Endocrinol1990;125:375-9.
26.
Gault VA, Irwin N., Green BD et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro 3) GIP administration improves glucose tolerance and ameliorated insul-n resistance and abnormalities of islet struture in obesity-related diabetes. Diabetes2005;54:2436-41.
27.
Miyawaki K. , Yamada Y., Ban et al. Inhibition of gastric inhibitory polypeptide signalling prevents obesity. Nat Med2002;8:738-42.
28.
Flatt PRDorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?Diabet Med2008;25:759-64.
29.
Murphy KG, Dhillo WS, Bloom SRGut peptides in the regulation of food intake and energy homeostasis . Endrocr Rev2006;27:719-27.
30.
Clements RH , Gonzalez Q., Long CJ et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type 2 diabetes mellitus. Am Surg2004;70:1-5.
